We use cookies to give you the best experience possible with our website and to improve our communication with you. We consider your selection and will only use the data you have approved us to gather.

These cookies help making a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

These cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously. With this information we can constantly improve the experience we offer on our website.

These cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.

Corporate News

13. September 2021

Geistlich Pharma becomes exclusive distribution partner for NUsurface®

Geistlich Pharma's Surgery business unit becomes the exclusive distribution partner for the NUsurface® meniscus implant in Switzerland and enters into an exclusive partnership with Active Implants. The objective of both companies is to support pain patients by preserving joints.

The NUsurface® meniscus implant from Active Implants is a meniscus replacement for patients with persistent knee pain after surgery on the medial meniscus. In individual cases, the meniscus replacement can close the gap between minimally invasive meniscus repair and complete knee replacement and thus prevent pronounced pain in the long term. NUsurface® is made of polycarbonate urethane (PCU), a medical plastic.

Implant mimics the function of the meniscus

Its unique material and composite structure and design require no fixation to bone or soft tissue. The superior feature is that the implant mimics the function of the natural meniscus, distributing the loads transmitted through the knee joint. The NUsurface® meniscus implant has been used in Europe since 2008 and in Israel since 2011 under CE registration.

Careful training of future users

For the introduction of the NUsurface® meniscus implant Geistlich follows its proven "No Train - No Use" approach. This involves future users going through a carefully structured training programme. The kick-off meeting was recently held with a handful of pioneer users, followed by a training programme at the Anatomical Institute of the Lucerne Cantonal Hospital. It is hoped that the circle of qualified physicians will be continuously expanded to include experienced specialists, thus enabling more patients in Switzerland to benefit from the implant.

PRESS CONTACT
Dr. Mirjam Kessler
Director Corporate Communications